Pantethine has beneficial effects on cholesterol and may reduce visceral fat
Olafur Pall Olafsson
abstracts. They are quite old but they do not seem to have been posted
on the group before. Although the results below were seen in patients
with hyperlipoproteinemia on the one hand and hypertriglyceridemia on
the other hand they do suggest that pantethine may be effective at
elevating HDL cholesterol, lowering LDL cholesterol and triglycerides,
as well as possibly inducing a favorable change in fat distribution.
As a result of my research I have decided to up my dose of pantethine.
I'll probably take a dose similar to the one used in these studies
(600-900mg daily) since it appears to be very safe at that dose.
Atherosclerosis. 1984 Jan;50(1):73-83. Related Articles, Links
Controlled evaluation of pantethine, a natural hypolipidemic
compound, in patients with different forms of hyperlipoproteinemia.
Gaddi A, Descovich GC, Noseda G, Fragiacomo C, Colombo L, Craveri
A, Montanari G, Sirtori CR.
Pantethine (P), the stable disulphate form of pantetheine, major
component and precursor of coenzyme A, was evaluated within a double-
blind protocol (8 weeks for P or for a corresponding placebo) in 29
patients, 11 with type IIB hyperlipoproteinemia, 15 with type IV, and
3 with an isolated reduction of high density lipoprotein cholesterol
(HDL-C) levels. In type IIB patients, P (300 mg t.i.d.) determined a
highly significant lowering of plasma total and low density
lipoprotein (LDL) associated cholesterol (-13.5% for both parameters).
In the same patients, HDL-C levels increased about 10% at the end of
treatment. Switching from P to placebo was associated with a rapid
return to the baseline cholesterolemia. Both in type IIB and type IV
patients, plasma triglyceride levels were reduced around 30%, when P
was given as the first treatment; when it was preceded by placebo,
reductions were less striking (respectively, -17.8% for type IIB and
-13.0% for type IV, at the end of P treatment). HDL-C levels were not
increased by P, either in type IV, and in the patients with low HDL
cholesterolemia. In type IV, LDL cholesterol levels showed a variable
response to P: they tended to increase when below 132 mg/dl, prior to
treatment, and to be reduced when above this level. This study
provides evidence for a significant hypocholesterolemic effect of P, a
natural compound free of overt side effects. It also indicates that P
may raise HDL-C levels in type IIB patients, while moderately reducing
triglyceridemia.
Publication Types:
* Clinical Trial
* Controlled Clinical Trial
* Research Support, Non-U.S. Gov't
PMID: 6365107 [PubMed - indexed for MEDLINE]
Related Links
* Effects of regular and extended-release gemfibrozil on
plasma lipoproteins and apolipoproteins in hypercholesterolemic
patients with decreased HDL cholesterol levels. [Atherosclerosis.
1996]
* The hypolipidemic action of probucol: a study of its effects
on high and low density lipoproteins. [J Lipid Res. 1983]
* Effects of nicotinic acid therapy on plasma lipoproteins and
very low density lipoprotein apoprotein C subspecies in
hyperlipoproteinemia. [J Clin Endocrinol Metab. 1982]
* Effects of two different fibric acid derivatives on
lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen
activator inhibitor and paraoxonase activity in type IIb
hyperlipoproteinaemia. [Atherosclerosis. 1998]
* Fenofibrate of gemfibrozil for treatment of types IIa and
IIb primary hyperlipoproteinemia: a randomized, double-blind,
crossover study. [Endocr Pract. 2002]
See all Related Articles...
J Atheroscler Thromb. 2000;7(1):55-8. Related Articles, Links
The effects of pantethine on fatty liver and fat distribution.
Osono Y, Hirose N, Nakajima K, Hata Y.
Health Administration Center, Aoyama Gakuin University, Tokyo,
Japan.
Although the prognosis of fatty liver depends on its causes, we
feel from our clinical experience that fatty liver with
hypertriglyceridemia has a good prognosis and responds well to
treatment. In this study, 600 mg/day of pantethine was administered to
16 outpatients with fatty liver and hypertriglyceridemia for six
months or longer to examine whether the drug improved fatty liver
using abdominal plain computed tomography (CT). Nine of the 16-
pantethine patients were no longer diagnosed as having fatty liver
after the study period. An chi2 test indicated the significant
disappearance of fatty liver. At the same time, the visceral fat
calculated from the CT image passing the umbilical region was also
significantly reduced. On the contrary, the subcutaneous fat area
tended to increase, so the ratio of the visceral-to-subcutaneous fat
area was reduced significantly. This indicates triglycerides may be
pooled in the body as hepato-visceral fat and subcutaneous fat, and
that pantethine may transfer fat from the liver and viscera to the
subcutaneous tissue. This suggests that visceral fat deposition and
fatty liver occurring with hypertriglyceridemia may have a common
basis, probably excessive matrixes, and that pantethine may
simultaneously improve the two conditions.
Publication Types:
* Clinical Trial
PMID: 11425046 [PubMed - indexed for MEDLINE]
Related Links
* Visceral fat accumulation and insulin resistance are
important factors in nonalcoholic fatty liver disease. [J
Gastroenterol. 2006]
* A novel method of measuring intra-abdominal fat volume using
helical computed tomography. [Int J Obes Relat Metab Disord. 2002]
* Relationships between tamoxifen use, liver fat and body fat
distribution in women with breast cancer. [Int J Obes Relat Metab
Disord. 2001]
* The prediction of visceral fat by dual-energy X-ray
absorptiometry in the elderly: a comparison with computed tomography
and anthropometry. [Int J Obes Relat Metab Disord. 2002]
* Hepatic steatosis in Cushing's syndrome: a radiological
assessment using computed tomography. [Eur J Endocrinol. 2003]
See all Related Articles...
betai...@yahoo.com
The problem is that it isn't cheap. I take a half or third
dose that to say about 200 milligrams per day
and hope synergisms will given results.
With my rather high dose TR niacin 400 mg TID, high dose betaine 3
capsules
of betaine HCL 10 grains TID and occassional
niacinamide instead of a niacin tablet, 10 mg of biotin per day,
a huge dose of inositol and all the other B's including
some regular B-5.
I will say a piece of personal experience, if I take
several capsules of betaine HCl with each meal in
addition to the 400 mg of TR niacin, I don't have
any flushing to speak of. I don't know whether
the betaine/trimethylglycine counteracts the blood
lipid benefits of niacin. In addition, the betaine
no doubt due to all the methyl groups it contributes
also blocks the skipped heartbeat I used to get
when I'd dial up the niacin or niacinamide dose beyond
about 100 mg per day.
I originally got on the betaine HCl to improve my digestion
and to prevent reflux and dyspepsia. I found it
in combination with an incline sleep position to be
99.7 percent effective for keeping my esophagus healthy
and my digestion trustworthy. The effect was profound
and clear-cut for me.
-------------------------------------------------------------------
Ted
Beyond a century sells 100 grams for $16. But there is no way I could
afford it. Too bad.
Olafur Pall Olafsson
> x-no-archive: yes
>
> Olafur Pall Olafsson wrote:
> > While researching pantethine I came accross these interesting
> > abstracts. They are quite old but they do not seem to have been posted
> > on the group before. Although the results below were seen in patients
> > with hyperlipoproteinemia on the one hand and hypertriglyceridemia on
> > the other hand they do suggest that pantethine may be effective at
> > elevating HDL cholesterol, lowering LDL cholesterol and triglycerides,
> > as well as possibly inducing a favorable change in fat distribution.
> > As a result of my research I have decided to up my dose of pantethine.
> > I'll probably take a dose similar to the one used in these studies
> > (600-900mg daily) since it appears to be very safe at that dose.
>
Thanks for the papers. I'm leaving them quoated below so they will be
archieved.
> Note that pantethine stimulates adrenal
> function. When I was adrenally suppressed, it worked well and lowered
> my LDL 70 points with no other changes (I'd already low carbed for
> years) and raised my HDL to 70 from about 60. Not only does it work,
> but it's safe and effective in renal failure and hepatitis patients, too.
>
> Unfortunately, I've got Cushing's syndrome, and pantethine stimulates
> adrenals. I not only lost the lipid effect, it now triggers
> hypertension when I'm hypercortisolemic (it's intermittent/cyclical).
Do you have any evidence that it stimulates adrenal function?
Doing a quick search on pubmed I did not find any evidence that
pantethine does so. I only found this abstract that indicates that a
deficiency in pantothenate may reduce adrenal function. But that does
not mean pantethine stimulates adrenal function, only that it corrects
any lack of adrenal function caused by pantethine deficiency.
Vopr Pitan. 1985 Jul-Aug;(4):51-4. Related Articles, Links
[Adrenal cortex functional activity in pantothenate deficiency and
the administration of the vitamin or its derivatives]
[Article in Russian]
Tarasov IuA, She bak VM, Mo seenok AG.
Study of the corticosteroid content in the adrenals and blood of
rats under pantothenate deficiency has demonstrated a decrease in
adrenocortical function. A single administration of pantothenate in a
dose of 3.3 mg/kg reduced the influence of hypovitaminosis on the
adrenals. The pantothenate derivatives (pantethine, 4'-
phosphopantothenate and CoA in particular) injected to intact animals
in a single dose equimolar to 3.3 mg/kg calcium pantothenate per kg bw
had a marked steroidogenous effect.
Publication Types:
* Comparative Study
* English Abstract
PMID: 4060684 [PubMed - indexed for MEDLINE]
Related Links
* [A change in the CoA concentration in the organs of young
rats following injection with pantothenate derivatives] [Vopr Med
Khim. 1974]
* Pantothenic acid in health and disease. [Vitam Horm. 1991]
* [Pantothenate metabolism in the rat liver and its
regulation] [Vopr Med Khim. 1977]
* [Metabolism of pantothenic acid and its derivatives in
animals deficient in this enzyme] [Ukr Biokhim Zh. 1987]
* [Distribution and biotransformation of labelled pantothenate
in cytoplasmic and mitochondrial fractions of the rat liver with a
deficiency of pantothenic acid] [Vopr Pitan. 1989]
See all Related Articles...
> [Evaluation of the cholesterol-lowering effectiveness of pantethine in
> women in perimenopausal age]
>
> [Article in Italian]
>
> Binaghi P, Cellina G, Lo Cicero G, Bruschi F, Porcaro E, Penotti M.
>
> Servizio di Cardiologia, Istitut Clinici di Perfezionamento, Milano.
>
> Cardiovascular diseases are the main cause of death also in women. Their
> incidence, rapidly growing in the peri-menopausal period, is related to
> serum levels of total cholesterol and its LDL fraction. It was also
> shown that the peroxidation of LDL is an additional factor in the
> genesis of atherosclerotic vascular disease. As long-term treatments
> with synthetic lipid-lowering drugs may cause undesirable side effects,
> while pantethine is known to be well tolerated, we treated 24
> hypercholesterolemic women (total serum cholesterol greater than or
> equal to 240 mg/dl), in perimenopausal age (range: 45-55 years, mean +/-
> SD = 51.6 +/- 2.4) with 900 mg/day of pantethine. This is a precursor of
> coenzyme A, with an antiperoxidation effect in vivo, and our aim was to
> confirm its lipid lowering activity in this particular type of patients.
> After 16 weeks of treatment, significant reductions of total
> cholesterol, LDL-cholesterol and LDL-C/HDL-C ratio could be observed. No
> remarkable changes of the main laboratory parameters (fasting blood
> sugar, B.U.N., creatinine, uric acid) were seen. Efficacy percentages of
> the treatment were about 80%. None of the patients complained of adverse
> reactions due to the treatment with pantethine. In conclusion, we
> suggest that pantethine should be considered in the long-term treatment
> of lipid derangements occurring in the perimenopausal age.
>
> PMID: 2359503 [PubMed - indexed for MEDLINE]
> 1: Acta Biomed Ateneo Parmense. 1984;55(1):25-42. Related Articles, Links
>
> [Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment
> with pantethine]
>
> [Article in Italian]
>
> Arsenio L, Caronna S, Lateana M, Magnati G, Strata A, Zammarchi G.
>
> The hypolipidemizing effects of Pantethine were investigated by the
> Authors in 37 hypercholesterolemic and/or hypertriglyceridemic patients.
> Of these, 21 were also diabetic, in a satisfying glucidic compensation,
> in order to verify the action of this drug also in this metabolic
> condition. The study was carried out for three months and during this
> period the patients were given Pantethine at the dose of 600 mg/die
> orally. At the 30th, the 60th, the 90th day of treatment the following
> parameters were controlled: cholesterolemia, HDL cholesterol,
> apolipoproteins A and B, triglyceridemia, systolic and diastolic
> arterial pressure, uricemia, body weight. Thirty days after suspending
> the treatment, the parameters were controlled again to detect a possible
> "rebound" effect. The results were analyzed on the whole case-record,
> subdividing the patients in dislipidemic and diabetic-dislipidemic, and
> on the basis of the Fredrickson's classification. Pantethine induced in
> all groups a quick and progressive decrease of cholesterolemia,
> triglyceridemia, LDL cholesterol and Apolipoproteins B with increased
> HDL cholesterol and Apolipoproteins A. After suspending the treatment,
> there is a clear inversion of the state of these parameters. The Authors
> conclude that the present work shows that Pantethine, a natural and
> atoxic substance, an important component of Coenzyme A, is efficacious
> in determining a clear tendency towards normalization of the lipidic values.
>
> PMID: 6232801 [PubMed - indexed for MEDLINE]
> 1: Atherosclerosis. 1984 Jan;50(1):73-83. Related Articles, Links
>
> Controlled evaluation of pantethine, a natural hypolipidemic compound,
> in patients with different forms of hyperlipoproteinemia.
>
> Gaddi A, Descovich GC, Noseda G, Fragiacomo C, Colombo L, Craveri A,
> Montanari G, Sirtori CR.
>
> Pantethine (P), the stable disulphate form of pantetheine, major
> component and precursor of coenzyme A, was evaluated within a
> double-blind protocol (8 weeks for P or for a corresponding placebo) in
> 29 patients, 11 with type IIB hyperlipoproteinemia, 15 with type IV, and
> 3 with an isolated reduction of high density lipoprotein cholesterol
> (HDL-C) levels. In type IIB patients, P (300 mg t.i.d.) determined a
> highly significant lowering of plasma total and low density lipoprotein
> (LDL) associated cholesterol (-13.5% for both parameters). In the same
> patients, HDL-C levels increased about 10% at the end of treatment.
> Switching from P to placebo was associated with a rapid return to the
> baseline cholesterolemia. Both in type IIB and type IV patients, plasma
> triglyceride levels were reduced around 30%, when P was given as the
> first treatment; when it was preceded by placebo, reductions were less
> striking (respectively, -17.8% for type IIB and -13.0% for type IV, at
> the end of P treatment). HDL-C levels were not increased by P, either in
> type IV, and in the patients with low HDL cholesterolemia. In type IV,
> LDL cholesterol levels showed a variable response to P: they tended to
> increase when below 132 mg/dl, prior to treatment, and to be reduced
> when above this level. This study provides evidence for a significant
> hypocholesterolemic effect of P, a natural compound free of overt side
> effects. It also indicates that P may raise HDL-C levels in type IIB
> patients, while moderately reducing triglyceridemia.
>
> Publication Types:
> · Clinical Trial
> · Controlled Clinical Trial
>
> PMID: 6365107 [PubMed - indexed for MEDLINE]
> 1: Int J Clin Pharmacol Ther Toxicol. 1986 Nov;24(11):630-7. Related
> Articles, Links
>
> Lipoprotein changes induced by pantethine in hyperlipoproteinemic
> patients: adults and children.
>
> Bertolini S, Donati C, Elicio N, Daga A, Cuzzolaro S, Marcenaro A,
> Saturnino M, Balestreri R.
>
> Following a brief outline of current knowledge concerning
> atherosclerosis and its treatment, the authors describe the results
> obtained by treating with pantethine (900-1200 mg daily for 3 to 6
> months) a series of 7 children and 65 adults suffering from
> hypercholesterolemia alone or associated with hypertriglyceridemia
> (types IIa and IIb of Fredrickson's classification). Pantethine
> treatment produced significant reduction of the better known risk
> factors (total cholesterol, LDL-cholesterol, triglycerides, and apo-B)
> and a significant increase of HDL-cholesterol (signally HDL2) and
> apolipoprotein A-I. The authors conclude with a discussion of these
> results and of the possible role of pantethine in the treatment of
> hyperlipoproteinemia, in view of its perfect tolerability and
> demonstrated therapeutic effectiveness.
>
> PMID: 3098691 [PubMed - indexed for MEDLINE]
> : Atherosclerosis. 1984 Dec;53(3):255-64. Related Articles, Links
>
> Pantethine reduces plasma cholesterol and the severity of arterial
> lesions in experimental hypercholesterolemic rabbits.
>
> Carrara P, Matturri L, Galbussera M, Lovati MR, Franceschini G, Sirtori CR.
>
> Pantethine (P), a coenzyme A precursor, was administered to
> cholesterol-fed rabbits (0.5% cholesterol diet + 1% pantethine) for 90
> days. At the end of treatment, plasma total cholesterol levels were
> reduced 64.7% and the HDL/total cholesterol ratio increased in P-treated
> animals; a significant rise of the apo A-I/A-II ratio was detected in
> HDL. VLDL lipid and protein levels were, on the other hand, reduced by
> P. The cholesterol-ester content of both liver and aortic tissues was
> not significantly affected by P. Although the total aortic area with
> evident plaques was reduced only 18.2%, the microscopical examination of
> sections from the major vessels of P-treated animals, showed a reduction
> in the severity of lesions, both in the aorta and in the coronary
> arteries. These findings suggest that P, in addition to significantly
> lowering plasma cholesterol levels in rabbits on an experimental diet,
> may modify lipid deposition in major arteries, possibly by affecting
> lipoprotein composition and/or exerting an arterial protective effect.
>
> PMID: 6442152 [PubMed - indexed for MEDLINE]
> Clin Ther. 1986;8(5):537-45. Related Articles, Links
>
> Effectiveness of long-term treatment with pantethine in patients with
> dyslipidemia.
>
> Arsenio L, Bodria P, Magnati G, Strata A, Trovato R.
>
> A one-year clinical trial with pantethine was conducted in 24 patients
> with established dyslipidemia of Fredrickson's types II A, II B, and IV,
> alone or associated with diabetes mellitus. The treatment was well
> tolerated by all patients with no subjective complaints or detectable
> side effects. Blood lipid assays repeated after 1, 3, 6, 9, and 12
> months of treatment revealed consistent and statistically significant
> reductions of all atherogenic lipid fractions (total cholesterol, ...
>
> read more »